Skip to main content
SpringerLink
Log in

PARK2 orchestrates cyclins to avoid cancer

  • News & Views
  • Published:

From Nature Genetics

View current issue Submit your manuscript

Proper control of cyclin-dependent kinases ensures coordinated cell cycle progression and guards against tumorigenesis. A new study identifies the PARK2 E3 ubiquitin ligase as an important coordinator of G1/S-phase cyclin turnover and explains how mutations targeting this key cell cycle regulatory node contribute to a range of cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: PARK2 in cyclin regulation and cancer.

References

  1. Morgan, D.O. The Cell Cycle: Principles of Control (New Science Press, London, New York, 2007).

    Google Scholar 

  2. Bartek, J. et al. Curr. Opin. Cell Biol. 8, 805–814 (1996).

    Article  CAS  PubMed  Google Scholar 

  3. Deshaies, R.J. & Joazeiro, C.A. Annu. Rev. Biochem. 78, 399–434 (2009).

    Article  CAS  PubMed  Google Scholar 

  4. Skaar, J.R. et al. Nat. Rev. Mol. Cell Biol. 14, 369–381 (2013).

    Article  CAS  PubMed  Google Scholar 

  5. Teixeira, L.K. & Reed, S.I. Annu. Rev. Biochem. 82, 387–414 (2013).

    Article  CAS  PubMed  Google Scholar 

  6. Gong, Y. et al. Nat. Genet. 46, 588–594 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Beroukhim, R. et al. Nature 463, 899–905 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Veeriah, S. et al. Nat. Genet. 42, 77–82 (2010).

    Article  CAS  PubMed  Google Scholar 

  9. Ciriello, G. Genome Res. 22, 398–406 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lücking, C.B. et al. N. Engl. J. Med. 342, 1560–1567 (2000).

    Article  PubMed  Google Scholar 

  11. Sarraf, S.A. et al. Nature 496, 372–376 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bartkova, J. et al. Nature 434, 864–870 (2005).

    Article  CAS  PubMed  Google Scholar 

  13. Halazonetis, T.D. et al. Science 319, 1352–1355 (2008).

    Article  CAS  PubMed  Google Scholar 

  14. Falck, J. et al. EMBO Rep. 13, 561–568 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bruyère, C. & Meijer, L. Curr. Opin. Cell Biol. 25, 772–779 (2013).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jiri Bartek and Zdenek Hodny are at the Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.,

    Jiri Bartek & Zdenek Hodny

  2. Jiri Bartek is also at the Danish Cancer Society Research Center, Copenhagen, Denmark.,

    Jiri Bartek

Authors
  1. Jiri Bartek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zdenek Hodny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jiri Bartek or Zdenek Hodny.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bartek, J., Hodny, Z. PARK2 orchestrates cyclins to avoid cancer. Nat Genet 46, 527–528 (2014). https://doi.org/10.1038/ng.2992

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.2992

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation